Ra Pharmaceuticals Inc

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Company

Indicator

Code Company Date Close Change Indicator Value Signal

Trading Performance

Donchian Channels

Score

0.8

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 15 22.9 0.27% 0.36% 47.4% -5.8% 126.4%
SHORT 16 28.0 0.38% 0.60% 22.1% -7.5% 57.1%

Summary

Technical Analysis


The Donchian channel is a useful indicator for seeing the volatility of a market price. If a price is stable the Donchian channel will be relatively narrow. If the price fluctuates a lot the Donchian channel will be wider. The two outer bands are plotted as the highest high and lowest low for a set period originally 20 days with the optional middle band calculated as the average of the two.

Calculation: Donchian Channels:
1) Upper Channel = 20 Day High;
2) Lower Channel = 20 Day Low;
3) Middle Channel = (20 Day High + 20 Day Low)/2;


PROFILE: Ra Pharmaceuticals Inc (RARX)


Stock Exchange: NASDAQ
Company: Ra Pharmaceuticals Inc
Ticker Codes: | RARX | NASDAQ:RARX |

About Ra Pharmaceuticals Inc (NASDAQ:RARX):

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Top 10:

Donchian Channels

Download
Company Close Change(%) Volume Value Signal
NYNY Empire Resorts Inc 9.68 14.6 187,517 -4.09 BEARISH
DHXM DHX Media Ltd 1.27 12.4 234,932 -13.6 BEARISH
TUSK Mammoth Energy Services 4.34 9.6 253,268 -31.82 BEARISH
BCOM B Communications 1.34 8.1 4,721 -9.92 BEARISH
BIDU Baidu Inc 104.22 7.7 10,306,342 -2.65 BEARISH
ACRS Aclaris Therapts 0.93 6.5 1,250,572 -35.04 BEARISH
NNBR Nn Inc 6.45 6.4 110,947 -30.48 BEARISH
WYNN Wynn Resorts 112.41 6.3 2,922,585 -23.56 BEARISH
YRCW Yrc Worldwide 2.62 5.6 1,297,157 -18.57 BEARISH
CCXI Chemocentryx 7.09 5.5 322,568 -7.14 BEARISH